• A 48-Year-Old Man With a Hip Fracture and Skin Rash: A Case Report
• A case of indolent systemic mastocytosis responding to treatment with Avapritinib
• A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis
• A multi-center retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML
• A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML
• A Vertebral Fracture Unmasking Systemic Mastocytosis in a 29-Year-Old Man
• Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity
• Acute Myeloid Leukemia t (8;21) with Masked Systemic Mastocytosis
• Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation
• Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
• Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
• Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell-Mediated Reactions
• An unusual presentation of systemic mastocytosis in a myelolipoma
• An Unusual Transition from Cutaneous to Systemic Mastocytosis in a Pediatric Patient
• An unusual yet treatable cause of recurrent abdominal pain
• Asymptomatic Systemic Mastocytosis Uncovered During Routine Colonoscopy: A Case Report
• Autoantibodies to type I interferons in patients with systemic mastocytosis
• Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation
• Avapritinib versus Placebo in Indolent Systemic Mastocytosis
• Beyond Midostaurin: Role of Avapritinib in Managing Systemic Mastocytosis
• Beyond the Usual Suspects: Unraveling Spleen Mastocytosis in Hypersplenism Differential Diagnosis
• Bullous Mastocytosis: A Rare Variant of Diffuse Cutaneous Mastocytosis
• Case Report: Mast cell anergy: absence of symptoms after accidental re-exposure to amoxicillin/clavulanic acid 3 days after anaphylaxis
• Challenges in the Diagnosis of Cutaneous Mastocytosis
• Characteristics of an ethnically diverse cohort of children with pediatric cutaneous mastocytosis: One institution's experience
• Cladribine (2-CdA) improves cutaneous manifestations, DLQI and MC-QoL of patients with mastocytosis
• Cladribine improves cutaneous manifestations, Dermatology Life Quality Index, and Mastocytosis Quality of Life of patients with mastocytosis
• Clinical and biological characteristics associated with bronchial or pulmonary abnormalities on chest CT imaging in patients with systemic mastocytosis
• Clinical spectrum of patients diagnosed with childhood mastocytosis: a retrospective single center experience
• Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
• CT and Fluorine-18-Fluorodeoxyglucose (18F-FDG) PET/CT Imaging Findings of Aggressive Systemic Mastocytosis: A Case Report
• Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?
• Diagnosis and management of systemic mastocytosis in a community hematology setting
• Diagnosis of systemic mastocytosis with cryptic deletion of TET2 and DNMT3A resulting from unbalanced translocation
• Diagnostic challenges in systemic mastocytosis with gastrointestinal symptoms
• Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders
• Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease
• Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants : Brief title: Drug-drug interaction of midostaurin
• Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study
• Epidemiology of mastocytosis: a population-based study (Sweden)
• Evaluation of a diagnostic algorithm for mastocytosis in skin biopsies and CD25 expression in skin mast cells of 49 patients followed up at a Tertiary Hospital in Sao Paulo, Brazil
• Factor VII Deficiency in Systemic Mastocytosis with an Associated Myeloid Neoplasm
• Flow cytometric immunophenotypic differentiation patterns of bone marrow eosinophilopoiesis
• Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment
• Histological characterization of liver involvement in systemic mastocytosis
• How I diagnose systemic mastocytosis
• Impact of Undiagnosed Systemic Mastocytosis on Cardiopulmonary Bypass
• Increased expression of formyl peptide receptor-1 by basophils from patients with mastocytosis
• Interactions Between Eosinophils and IL5Ralpha+ Mast Cells in Non-Advanced Systemic Mastocytosis
• Intestinal perforation secondary to systemic mastocytosis: Report of an exceptional case
• KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine
• Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast Cells
• Mast cell activation syndrome: Current understanding and research needs
• Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes
• Mastocytoma
• Mastocytosis in the skin in dogs: A multicentric case series
• Metformin: A potential adjunct for treatment of systemic mastocytosis
• Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants
• Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis
• NCCN Guidelines Insights: Systemic Mastocytosis, Version 3.2024
• No indication of aberrant neutrophil extracellular trap release in indolent or advanced systemic mastocytosis
• Papular-purpuric "gloves and socks" syndrome in systemic mastocytosis treated with imatinib: a diagnostic challenge
• Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis
• Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in <em>KIT</em> D816V-Negative Advanced Systemic Mastocytosis
• Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis
• Prevalence and impact of the KIT M541L variant in patients with mastocytosis
• Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry
• Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis
• Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis
• Reply to: Successful Isatuximab Desensitization in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis
• Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
• Risk factors for severe sting reactions and side effects during venom immunotherapy
• Safety of a mRNA COVID-19 Vaccine in Patients with Indolent Systemic Mastocytosis
• Septic Peritonitis Secondary to Neoplasia in Two Canine Cancer-Bearing Patients Lacking Gastrointestinal and Hepatic Organ Rupture
• Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM
• SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis
• Splinter haemorrhages in a patient with systemic mastocytosis and hypereosinophilia
• Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy
• Standardized indolent systemic mastocytosis evaluations across a healthcare system: implications for screening accuracy
• Subcellular expression of CD30 in cutaneous mastocytosis-An important factor for targeted treatment
• Successful Desensitization to Isatuximab in a Patient With Refractory Multiple Myeloma and Indolent Systemic Mastocytosis. Reply to: Anaphylactic Shock due to Isatuximab and Successful Desensitization
• Successful isatuximab desensitization in a patient with refractory multiple myeloma and indolent systemic mastocytosis
• Synthetic abnormal mast cell particles successfully mimic neoplastic mast cells by flow cytometry
• Systemic Mastocytosis
• Systemic Mastocytosis Imitating Eosinophilic Enterocolitis
• Systemic mastocytosis: dying or survivin
• T-cell immune profile in blood of systemic mastocytosis: Association with disease features
• The Clinical Features of Hereditary Alpha-Tryptasemia
• The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis on clinical symptoms using conventional culture and next generation sequencing
• The Pivotal Role of Whole Genome and Transcriptome Sequencing in a Rare Case of Systemic Mastocytosis with Associated Myelodysplastic/Myeloproliferative Neoplasm with Neutrophilia
• The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients
• TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
• Treatment refractory mast cell leukemia with dominant gastrointestinal manifestation and concomitant skin symptoms: A case report
• Tumor necrosis factor alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
• TurboID-Based IRE1 Interactome Reveals Participants of the Endoplasmic Reticulum-Associated Protein Degradation Machinery in the Human Mast Cell Leukemia Cell Line HMC-1.2
• Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review
• Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal
• Unraveling the Rare Entity of KIT D816V-Negative Systemic Mastocytosis
• Urticaria pigmentosa and systemic mastocytosis
• Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow